Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Dermatology

Biology, Pathology, and Your Test Results

At a Glance

Linear IgA dermatosis is supported by a continuous line of IgA along the skin’s basement membrane on direct immunofluorescence. Biopsy site, specimen handling, salt-split results, and clinical symptoms help confirm the diagnosis and separate look-alike blistering diseases.

Understanding why your skin is blistering requires looking deep into the biology of your immune system. In Linear IgA Dermatosis (LAD), the body’s defense system becomes confused and begins producing autoantibodies—specifically a type called IgA—that attack the very proteins that anchor your skin to your body [1][2].

The Biological “Glue” Under Attack

Your skin is made of layers. The “glue” that holds the top layer (epidermis) to the bottom layer (dermis) is called the basement membrane zone (BMZ) [1]. In LAD, IgA antibodies target specific proteins within this zone:

  • LAD-1 and LABD97: These are common targets. They are actually fragments of a larger protein called BP180 (or type XVII collagen) [2][3].
  • The Chain Reaction: Once the IgA antibodies latch onto these proteins, they “call for backup” by recruiting neutrophils, a type of white blood cell [4]. These neutrophils release enzymes that dissolve the BMZ glue, causing the skin layers to separate and fill with fluid, creating the blisters you see [5][6].

Decoding Your Test Results

To confirm LAD, doctors use two main types of tests. It is important to know that a standard skin biopsy (H&E histology) is rarely enough for a final diagnosis because it only shows the “aftermath” (a blister filled with neutrophils), which can look like many other diseases [7][8].

The Biopsy Difference

  • Lesional Biopsy (for Routine H&E): Taken directly from a blister. This shows doctors what the damage looks like under a microscope (a “subepidermal split” with neutrophils).
  • Perilesional Biopsy (for DIF): Taken from normal-looking skin right next to a fresh blister [9]. This is the critical test to see the IgA pattern.

The Gold Standard: Direct Immunofluorescence (DIF)

Using the perilesional skin, the lab uses a special glowing dye to see where the IgA is sitting.

  • The LAD Pattern: The characteristic finding is a continuous, linear (straight-line) deposit of IgA along the basement membrane [10][6].
  • Understanding False Negatives: If this line is broken or weak, it does not automatically rule out LAD. Biopsy site selection, lesion age, and specimen handling can all produce false negatives [11][12].

Salt-Split Skin Testing

If your blood is tested using indirect immunofluorescence (IIF), the lab may perform a “salt-split” test. They use a salt solution to intentionally separate the skin layers and see where your antibodies bind [2].

  • Roof Binding (Epidermal): This is common in LAD and suggests the antibodies are attacking the BP180/LAD-1 proteins [2][13].
  • Floor Binding (Dermal): This can occur in a specific subtype of LAD where the antibodies attack Type VII collagen [14]. This pattern can look very similar to another disease called Epidermolysis Bullosa Acquisita (EBA) [15].

How LAD Differs from “Look-Alikes”

Because several diseases cause blisters, your pathology report helps rule out these mimics:

  • Dermatitis Herpetiformis (DH): While DH also involves IgA, the pattern is granular (clumpy) rather than linear [16][9]. DH is closely linked to celiac disease, whereas LAD is not. (Do not start a gluten-free diet without discussing formal testing with your care team first) [17].
  • Bullous Pemphigoid (BP): This is the most common blistering disease in adults. It primarily involves IgG antibodies rather than IgA [18][9].

Helpful Elements for Your Diagnosis

A strong diagnosis usually brings together several findings. While you should never interpret the raw report without your dermatologist and pathologist, helpful elements on your records include:

  • DIF Result: Specifically notes “Linear IgA” along the basement membrane zone [10].
  • Immune Reactants: May list whether other proteins like C3 or IgG were also found as supportive findings [6][2].
  • Clinical Correlation: Your dermatologist will link the microscopic findings to your specific symptoms (like the “string of pearls” appearance) [8].

Common questions in this guide

What does a linear IgA pattern mean on my biopsy?
A linear IgA pattern means IgA antibodies are arranged in a continuous line along the basement membrane, the boundary between the outer and deeper layers of skin. This finding supports linear IgA dermatosis, but your dermatologist interprets it with your symptoms and other test results.
Why do doctors take biopsies from both a blister and nearby normal-looking skin?
A sample from the blister is used for routine microscopy to show how the skin layers separated and whether neutrophils are present. A sample of normal-looking skin beside a fresh blister is used for direct immunofluorescence, which detects the IgA pattern.
Can a negative immunofluorescence test still be compatible with LAD?
Yes. A weak or negative result can happen when the biopsy site is not ideal, the blister is older, or the specimen is not handled properly. If your symptoms still suggest LAD, your dermatologist may discuss another biopsy or blood tests.
What does roof or floor binding mean on a salt-split test?
Roof binding means antibodies attach to the epidermal side and is common in LAD, often pointing to proteins such as BP180 or LAD-1. Floor binding can occur when antibodies target type VII collagen and may resemble epidermolysis bullosa acquisita, so a specialist must interpret the result.
How can the pathology report distinguish LAD from other blistering diseases?
LAD usually produces a continuous linear IgA pattern, while dermatitis herpetiformis usually produces a clumpy or granular IgA pattern. Bullous pemphigoid more often involves IgG antibodies, so the immunofluorescence pattern, symptoms, and other tests are considered together.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Linear IgA dermatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my pathology report show a 'linear' or 'granular' pattern of IgA?
  2. 2.Was the biopsy for the immunofluorescence test taken from 'perilesional' skin (the clear skin next to a blister), and if so, how does that confirm my diagnosis?
  3. 3.If my salt-split skin test showed IgA on the 'floor' (dermal side), does that mean I might have a subtype like IgA EBA?
  4. 4.Which specific proteins (like BP180 or LAD-1) are my antibodies attacking, and does that change my treatment plan?
  5. 5.If my initial biopsy was negative but my symptoms look like LAD, should we consider a repeat biopsy or additional blood tests?

References

References (18)
  1. 1

    S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology.

    Caux F, Patsatsi A, Karakioulaki M, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2024; (38(6)):1006-1023 doi:10.1111/jdv.19880.

    PMID: 38421060
  2. 2

    Autoantibody Profile of a Cohort of 54 Italian Patients with Linear IgA Bullous Dermatosis: LAD-1 Denoted as a Major Auto-antigen of the Lamina Lucida Subtype.

    Cozzani E, Di Zenzo G, Gasparini G, et al.

    Acta dermato-venereologica 2020; (100(4)):adv00070 doi:10.2340/00015555-3415.

    PMID: 32011724
  3. 3

    Improvement of immunological tests for detecting autoantibodies in patients with lamina lucida-type linear IgA bullous dermatosis.

    Tsutsumi M, Koga H, Teye K, et al.

    Journal of dermatological science 2025; (117(1)):2-7 doi:10.1016/j.jdermsci.2024.12.001.

    PMID: 39732612
  4. 4

    Anti-NC16A IgA from Patients with Linear IgA Bullous Dermatosis Induce Neutrophil-Dependent Subepidermal Blistering in Mice.

    Jing K, Jordan TJM, Li N, et al.

    The Journal of investigative dermatology 2024; (144(1)):24-32.e1 doi:10.1016/j.jid.2023.05.027.

    PMID: 37437774
  5. 5

    Anti-FcαRI Monoclonal Antibodies Resolve IgA Autoantibody-Mediated Disease.

    Bos A, Aleyd E, van der Steen LPE, et al.

    Frontiers in immunology 2022; (13()):732977 doi:10.3389/fimmu.2022.732977.

    PMID: 35371001
  6. 6

    Linear IgA bullous dermatosis: 32 years of experience.

    Atci T, Pehlivan Ulutas G, Güreler Sirkeci E, Küçükoğlu R

    Anais brasileiros de dermatologia 2025; (100(2)):277-282 doi:10.1016/j.abd.2024.03.015.

    PMID: 39665877
  7. 7

    Linear IgA bullous dermatosis of childhood.

    Nasri J, Jungo P, Blickenstorfer M, et al.

    Dermatology online journal 2022; (28(5)) doi:10.5070/D328559270.

    PMID: 36809139
  8. 8

    Histopathologic Overlap Between Bullous Lupus Erythematosus and Linear IgA Bullous Dermatosis: A Comparative Study.

    Murugesu L, Tirumalae R

    The American Journal of dermatopathology 2024; (46(11)):739-745 doi:10.1097/DAD.0000000000002825.

    PMID: 39288759
  9. 9

    State-of-the-art diagnosis of autoimmune blistering diseases.

    van Beek N, Holtsche MM, Atefi I, et al.

    Frontiers in immunology 2024; (15()):1363032 doi:10.3389/fimmu.2024.1363032.

    PMID: 38903493
  10. 10

    A clinical and serological study of linear IgA bullous dermatosis without linear immunoglobulin deposition other than IgA at the basement membrane zone using direct immunofluorescence.

    Ohata C, Ishii N, Koga H, Nakama T

    The British journal of dermatology 2017; (177(1)):152-157 doi:10.1111/bjd.15232.

    PMID: 27943257
  11. 11

    Updates in the Diagnosis and Management of Linear IgA Disease: A Systematic Review.

    Shin L, Gardner JT, Dao H

    Medicina (Kaunas, Lithuania) 2021; (57(8)) doi:10.3390/medicina57080818.

    PMID: 34441024
  12. 12

    Linear IgA bullous dermatosis-a fifty year experience of Warsaw Center of bullous diseases.

    Kowalewski C, Wozniak K

    Frontiers in immunology 2024; (15()):1478318 doi:10.3389/fimmu.2024.1478318.

    PMID: 39877369
  13. 13

    Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults.

    Gottlieb J, Ingen-Housz-Oro S, Alexandre M, et al.

    The British journal of dermatology 2017; (177(1)):212-222 doi:10.1111/bjd.15244.

    PMID: 27995619
  14. 14

    Sublamina densa-type linear IgA bullous dermatosis with IgA autoantibodies specific for type VII collagen: a case report and clinicopathological review of 32 cases.

    Utsunomiya N, Chino T, Oyama N, et al.

    Dermatology online journal 2017; (23(11)).

    PMID: 29447635
  15. 15

    Epidermolysis Bullosa Acquisita-Current and Emerging Treatments.

    Tešanović Perković D, Bukvić Mokos Z, Marinović B

    Journal of clinical medicine 2023; (12(3)) doi:10.3390/jcm12031139.

    PMID: 36769788
  16. 16

    A Comparative Study of Direct Immunofluorescence Patterns in Linear IgA Bullous Dermatosis Versus Dermatitis Herpetiformis.

    Sagut P, Lyles E, Vroman J, et al.

    The American Journal of dermatopathology 2024; (47(7)):505-511 doi:10.1097/DAD.0000000000002864.

    PMID: 39570799
  17. 17

    Consensus on the treatment of autoimmune bullous dermatoses: dermatitis herpetiformis and linear IgA bullous dermatosis - Brazilian Society of Dermatology.

    Vale ECSD, Dimatos OC, Porro AM, Santi CG

    Anais brasileiros de dermatologia 2019; (94(2 Suppl 1)):48-55 doi:10.1590/abd1806-4841.2019940208.

    PMID: 31166403
  18. 18

    Linear IgA bullous dermatosis associated with immunotherapy.

    Momin B, Nguyen TF, Glade D, Messer A

    Dermatology online journal 2023; (29(6)) doi:10.5070/D329662995.

    PMID: 38478666

This page is for informational purposes only and is not medical advice. It explains how Linear IgA dermatosis affects the skin and how biopsy and immunofluorescence findings are used; your dermatologist and pathologist should interpret your report.